TLR3-and MyD88-dependent signaling differentially influences the development of west nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate

Journal of Virology

Volumn 87, Issue 22, 2013, Pages 12090-12101

  Xia, Jingya ^a   Winkelmann, Evandro R ^a   Gorder, Summer R ^b   Mason, Peter W ^a,c   Milligan, Gregg N ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Microbial Molecular Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD69 ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2C; INTERFERON; LIVE VACCINE; MYELOID DIFFERENTIATION FACTOR 88; REPLIVAX WN VACCINE; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; WEST NILE VACCINE; MYD88 PROTEIN, MOUSE; TLR3 PROTEIN, MOUSE; VIRUS ANTIBODY;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BIOLUMINESCENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; MEMORY CELL; MOUSE; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; WEST NILE FEVER; WEST NILE FLAVIVIRUS; ADAPTIVE IMMUNITY; ANIMAL; BLOOD; C57BL MOUSE; CD8+ T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; IMMUNOGLOBULIN PRODUCING CELL; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MALE; PHYSIOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-PRODUCING CELLS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 84886261898     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01469-13     Document Type: Article

References (61)

1. CDC. 2012. West Nile Virus (WNV) human infections reported to ArboNET, by state, United States, 1999-2012. CDC, Atlanta, GA. http://www.cdc.gov/ncidod/dvbid/westnile/surv&control.htm.
2. Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. 2011. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigated to the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203:75-84.
3. Posadas-Herrera G, Inoue S, Fuke I, Muraki Y, Mapua CA, Khan AH, Parquet Mdel C, Manabe S, Tanishita O, Ishikawa T, Natividad FF, Okuno Y, Hasebe F, Morita K. 2010. Development and evaluation of a formalin-inactivated West Nile virus vaccine (WN-VAX) for a human vaccine candidate. Vaccine 28:7939-7946.
4. Suzuki R, Winkelmann ER, Mason PW. 2009. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J. Virol. 83:1870-1880.
5. Nelson MH, Windelmann E, Ma Y, Xia J, Mason PW, Bourne N, Milligan GN. 2010. Immunogenicity of RepliVAX WN, a novel singlecycle West Nile virus vaccine. Vaccine 29:174-182.
6. Winkelmann ER, Widman DG, Xia J, Ishikawa T, Miller-Kittrell M, Nelson MH, Bourne N, Scholle F, Mason PW, Milligan GN. 2011. Intrinsic adjuvanting of a novel single-cycle flavivirus in the absence of type I interferon receptor signaling. Vaccine 30:1465-1475.
7. Widman DG, Ishikawa T, Winkelmann ER, Infante E, Bourne N, Mason PW. 2009. RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine 27:5550-5553.
8. Widman DG, Ishikawa T, Giavedoni LD, Hodara WL, Garza Mde L, Montalbo JA, Travassos Da Rosa AP, Tesh RB, Patterson JL, Carrion R, Jr, Bourne N, Mason PW. 2010. Evaluation of RepliVAX WN, a singlecycle flavivirus vaccine, in a non-human primate model of West Nile virus infection. Am. J. Trop. Med. Hyg. 82:1160-1167.
9. Ioanidis I, Ye F, McNally B, Willette M, Flano E. 2013. TLR expression and induction of type I and type III interferons in primary airway epithelial cells. J. Virol. 87:3261-3270.
10. Sun Y, Liu G, Li Z, Chen Y, Liu Y, Liu B, Su Z. 2012. Modulation of dendritic cell function and immune response by cysteine protease inhibitor from murine nematode parasite Heligmosomoides polygyrus. Immunology 138:370-381.
11. Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, Kopf M, Marsland BJ. 2007. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 178: 2182-2191.
12. Kawai T, Akira S. 2008. Toll-like receptor and RIG-I-like receptor signaling. Ann. N. Y. Acad. Sci. 1143:1-20.
13. Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, Polhemus ME, Yadava A. 2012. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 30: 3311-3319.
14. Bessa J, Kopf M, Bachmann MF. 2010. Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J. Immunol. 184:4615-4619.
15. Jeisy-Scott V, Kim JH, Davis WG, Cao W, Katz JM, Sambhara S. 2012. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice. J. Virol. 86:10988-10998.
16. Yu P, Lubben W, Slomka H, Gebler J, Konert M, Cai C, Neubrandt L, da Costa OP, Paul S, Dehnert S, Dohne K, Thanisch M, Storsberg S, Wiegand L, Kaufmann A, Nain M, Quintabilla-Martinez L, Bettiio S, Schnierle B, Kolesnikova L, Becker S, Schnare M, Bauer S. 2012. Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity 37:867-879.
17. Siddiqui S, Basta S. 2011. CD8+ T cell immunodominance in lymphocytic choriomeningitis virus infection is modified in the presence of Tolllike receptor agonists. J. Virol. 85:13224-13233.
18. Pulendran B, Ahmed R. 2006. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 124:849-863.
19. Widman DG, Ishikawa T, Fayzulin R, Bourne N, Mason PW. 2008. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 26:2762-2771.
20. Gilfoy F, Fayzulin R, Mason PW. 2008. West Nile virus genome amplification requires the functional activities of the proteasome. Virology 385: 74-84.
21. Rossi SL, Zhao Q, O'Donnell VK, Mason PW. 2005. Adaptation of West Nile virus replicons to cells in culture and use of replicon-bearing cells to probe antiviral action. Virology 331:457-470.
22. Kneitz R-H, Schubert J, Tollmann F, Zens W, Hedman K, Weissbrich B. 2004. A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid. BMC Infect. Dis. 4:33-43.
23. Takaqi H, Fukaya T, Eizumi K, Sato Y, Sato K, Shibazaki A, Otsuka H, Hijikata A, Watanabe T, Ohara O, Kaisho T, Malissen B, Sato K. 2011. Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo. Immunity 35:958-971.
24. Minquet S, Dopfer EP, Pollmer C, Freudenberg MA, Galanos C, Reth M, Huber M, Schamel WW. 2008. Enhanced B-cell activation mediated by TLR4 and BCR crosstalk. Eur. J. Immunol. 38:2475-2487.
25. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM. 2010. Type I IFN enhances follicular B cell contribution to the T cellindependent antibody response. J. Exp. Med. 207:1485-1500.
26. Purtha WE, Chachu KA, Wirgin HW, IV, Diamond MS. 2008. Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J. Virol. 82:10964-10974.
27. Rodriguez-Pinto D. 2005. B cells as antigen presenting cells. Cell. Immunol. 238:67-75.
28. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. 2011. Molecular programming of B cell memory. Nat. Rev. Immunol. 12:24-34.
29. Jing X, Zhao DM, Waldschmidt TJ, Xue HH. 2008. GABPβ2 is dispensible for normal lymphocyte development but moderately affects B cell responses. J. Biol. Chem. 283:24326-24333.
30. Mineo TW, Oliveira CJ, Gutierrez FR, Silva JS. 2010. Recognition by Toll-like receptor 2 induces antigen-presenting cell activation and Th1 programming during infection by Neospora caninum. Immunol. Cell Biol. 88:825-833.
31. Kumar H, Koyama S, Ishii KJ, Kawai T, Akira S. 2008. Cutting edge: cooperation of IPS-1-and TRIF-dependent pathways in poly ICenhanced antibody production and cytotoxic T cell responses. J. Immunol. 180:683-687.
32. Good-Jacoboson KL, Tarlinton DM. 2012. Multiple routes to B-cell memory. Int. Immunol. 24:403-408.
33. Hofmeister Y, Planitzer CB, Farcet MR, Teschner W, Butterweck HA, Holzer GW, Kreil TR. 2011. Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus. J. Virol. 85:1896-1899.
34. Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, Ross TM. 2010. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol. J. 7:95. doi:10.1186/1743-422X-7-95.
35. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198:1853-1862.
36. Diamond MS, Pierson TC, Fremont DH. 2008. The structural immunology of antibody protection against West Nile virus. Immunol. Rev. 225:212-225.
37. Daffis S, Samuel MA, Suthar MS, Gale M, Jr, Diamond MS. 2008. Toll-like receptor 3 has a protective role against West Nile virus infection. J. Virol. 82:10349-10358.
38. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10:1366-1373.
39. Szretter KJ, Daffis S, Patel J, Suthar MS, Klein RS, Gale M, Jr, Diamond MS. 2010. The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of central nervous system. J. Virol. 84:12125-12138.
40. Guay HM, Andreyeva TA, Garvea RL, Welsh RM, Szomolanyi-Tsuda E. 2007. MyD88 is required for the formation of long-term humoral immunity to virus infection. J. Immunol. 178:5124-5131.
41. Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, DeFranco AL. 2011. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of antiviral germinal center response. Immunity 34:375-384.
42. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15:34-41.
43. Boeglin E, Smulski CR, Brun S, Milosevic S, Schneider P, Fournel S. 2011. Toll-like receptor agonists synergize with CD40L to induce either proliferation or plasma cell differentiation of mouse B cells. PLoS One 6:e25542. doi:10.1371/journal.pone.0025542.
44. Coro ES, Chang WL, Baumgarth N. 2006. Type I IFN rectpror signals directly stimulate local B cells early following influenza virus infection. J. Immunol. 176:4343-4351.
45. Kang S-M, Yoo D-G, Kim M-G, Song J-M, Park M-K, Eunju O, Quan FS, Akira S, Compans RW. 2011. MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination. J. Virol. 85:11391-11400.
46. Neves P, Lampropoulou V, Calderon-Gomez E, Roch T, Stervbo U, Shen P, Kuhl AA, Lodderkemper C, Haury M, Nedospasov SV, Kaufmann SH, SteinhoffU, Calado DP, Fillatreau S. 2010. Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity 33:777-790.
47. Gargano LM, Moser JM, Speck SH. 2008. Role for MyD88 signaling in marine gammaherpesvirus 68 latency. J. Virol. 82:3853-3863.
48. Browne EP. 2011. Toll-like receptor 7 controls the anti-retroviral germinal center response. PLoS Pathog. 7:e1002293. doi:10.1371/journal.ppat.1002293.
49. Bessa J, Kopf M, Bachmann MF. 2010. Cutting edge: IL-21 and TLR signaling relate germinal center responses in a B cell-intrinsic manner. J. Immunol. 185:4615-4619.
50. Shlomchik MJ, Weisel F. 2012. Germinal center selection and the development of memory B and plasma cells. Immunol. Rev. 247:52-63.
51. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, Hartmenn G. 2005. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174:4043-4050.
52. Finkelman FD, Scetic A, Gresser I, Snapper C, Holmes J, Trotta PP, Katona IM, Gause WC. 1991. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J. Exp. Med. 174:1179-1188.
53. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. 2001. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461-470.
54. Pone EJ, Zan H, Zhang J, Qahtani AI-A, Xu Z, Casali P. 2010. Toll-like receptors and B-cell receptors synergize to induce immunoglobulin classswitch DNA recombination: relevance to microbial antibody responses. Crit. Rev. Immunol. 30:1-29.
55. Pone EJ, Xu Z, White CA, Zan H, Casali P. 2012. B cell TLRs and induction of immunoglobulin class-switch DNA recombination. Front. Biosci. 17:2594-2615.
56. Minquet S, Dopfer EP, Schamel WW. 2010. Low-valency, but not monovalent, antigens trigger the B-cell antigen receptor (BCR). Int. Immunol. 22:205-212.
57. Winkler G, Randolph VB, Cleaves GR, Ryan TE, Stollar V. 1988. Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer. Virology 162:187-196.
58. Crooks AJ, Lee JM, Easterbrook LM, Timofeev AV, Stephenson JR. 1994. The NS1 of tick-borne encephalitis virus forms multimeric species upon secretion from the host cell. J. Gen. Virol. 75:3453-3460.
59. Chung KM, Thompson BS, Fremont DH, Diamond MS. 2007. Antibody recognition of cell surface-associated NS1 triggers Fc-g receptor-mediated phagocytosis and clearance of West Nile virus-infected cells. J. Virol. 81: 9551-9555.
60. Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS. 2011. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcγ receptor and complement-dependent effector mechanisms. J. Virol. 85: 11567-11580.
61. Mason PM, Shustov AV, Frolov I. 2006. Production and characterization of vaccines based on flaviviruses defective in replication. Virology 351: 432-443.